Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story

This review provides an update on the current state of pharmacogenetic research in the treatment of Alzheimer's disease (AD) and Lewy body disease (LBD) as it pertains to the use of cholinesterase inhibitors (ChEI). AD and LBD are first reviewed from clinical and pathophysiological perspectives...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Benjamin, Hollingdrake, Elizabeth, Kennedy, James L, Black, Sandra E, Masellis, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525201/
https://www.ncbi.nlm.nih.gov/pubmed/20038497
http://dx.doi.org/10.1186/1479-7364-4-2-91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525201/
https://www.ncbi.nlm.nih.gov/pubmed/20038497
http://dx.doi.org/10.1186/1479-7364-4-2-91

Ejemplares similares